Koers Kancera AB (publ) Nasdaq Stockholm
Aandelen
SE0015658570
Biotechnologie & Medisch Onderzoek
Omzet 2023 | 1,03 mln. 95,7K 88,9K | Omzet 2024 * | - | Marktkapitalisatie | 184 mln. 17,05 mln. 15,84 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2023 | -64 mln. -5,92 mln. -5,5 mln. | Nettowinst (verlies) 2024 * | -81 mln. -7,49 mln. -6,96 mln. | EV/omzet 2023 | 358 x |
Nettoliquiditeiten 2023 * | - 0 0 | Nettoliquiditeiten 2024 * | - 0 0 | EV/omzet 2024 * | - |
K/w-verhouding 2023 |
-9,28
x | K/w-verhouding 2024 * |
-2,17
x | Werknemers | - |
Dividendrendement 2023 * |
-
| Dividendrendement 2024 * |
-
| Vrij verhandelbaar | 37,38% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Peter Selin
CEO | Chief Executive Officer | - | 01-03-22 |
Director of Finance/CFO | 75 | - | |
Martin Norin
COO | Chief Operating Officer | 65 | 01-01-10 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 63 | 05-05-10 | |
Director/Board Member | 66 | 01-01-16 | |
Håkan Mellstedt
FOU | Founder | 82 | 28-04-10 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+8,96% | 105 mld. | |
-1,43% | 104 mld. | |
+4,40% | 22,94 mld. | |
-12,15% | 22,34 mld. | |
-4,36% | 19,25 mld. | |
-39,98% | 17,08 mld. | |
-10,04% | 16,96 mld. | |
+6,79% | 14,16 mld. | |
+38,61% | 12,63 mld. |